Dual targeting of DNA gyrase and topoisomerase IV: Target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 11, 2002, Pages 3370-3380

  Ince, Dilek ^a   Zhang, Xiamei ^a   Silver, L Christine ^a   Hooper, David C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GARENOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SEQUENCE; DRUG TARGETING; ENZYME ACTIVITY; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENOTYPE; MICROBIAL GENETICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; SEQUENCE ANALYSIS; STAPHYLOCOCCUS AUREUS;

ALLELES; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; CLONING, MOLECULAR; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INDOLES; MICROBIAL SENSITIVITY TESTS; MUTATION; PLASMIDS; QUINOLONES; STAPHYLOCOCCUS AUREUS;

EID: 0036841303     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.11.3370-3380.2002     Document Type: Article

References (56)

1. Baguley, B. C., and L. R. Ferguson. 1998. Mutagenic properties of topoisomerase-targeted drugs. Biochim. Biophys. Acta Gene Struct. Expression 1400:213-222.
2. Ball, P. 2000. Quinolone generations: natural history or natural selection? J. Antimicrob. Chemother. 46:17-24.
3. Bisognano, C., P. E. Vaudaux, D. P. Lew, E. Y. W. Ng, and D. C. Hooper. 1997. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Antimicrob. Agents Chemother. 41:906-913.
4. Boswell, F. J., J. M. Andrews, and R. Wise. 2001. Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae. J. Antimicrob. Chemother. 48:446-447.
5. Champoux, J. J. 2001. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70:369-413.
6. Discotto, L. F., L. E. Lawrence, K. L. Denbleyker, and J. F. Barrett. 2001. Staphylococcus aureus mutants selected by BMS-284756. Antimicrob. Agents Chemother. 45:3273-3275.
7. Domagala, J. M. 1994. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 33:685-706.
8. Elsea, S. H., Y. Hsiung, J. L. Nitiss, and N. Osheroff. 1995. A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine. J. Biol. Chem. 270:1913-1920.
9. Fass, D., C. E. Bogden, and J. M. Berger. 1999. Quaternary changes in topoisomerase II may direct orthogonal movement of two DNA strands. Nat. Struct. Biol. 6:322-326.
10. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
11. Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653.
12. Fournier, B., and D. C. Hooper. 1998. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrob. Agents Chemother. 42:121-128.
13. Friedman, S. M., T. Lu, and K. Drlica. 2001. Mutation in the DNA gyrase A gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob. Agents Chemother. 45:2378-2380.
14. Fukuda, H., and K. Hiramatsu. 1999. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:410-412.
15. Fung-Tomc, J., L. Valera, B. Minassian, D. Bonner, and E. Gradelski. 2001. Activity of the novel des-fluoro(6) quinolone BMS-284756 against methicillin-susceptible and -resistant staphylococci. J. Antimicrob. Chemother. 48:735-738.
16. Fung-Tomc, J. C., B. Minassian, B. Kolek, E. Huczko, L. Aleksunes, T. Stickle, T. Washo, E. Gradelski, L. Valera, and D. P. Bonner. 2000. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob. Agents Chemother. 44:3351-3356.
17. Hane, M. W., and T. H. Wood. 1969. Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. J. Bacteriol. 99:238-241.
18. Hartman-Neumann, S., K. Denbleyker, L. A. Pelosi, L. E. Lawrence, J. F. Barrett, and T. J. Dougherty. 2001. Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756. Antimicrob. Agents Chemother. 45:2865-2870.
19. Heaton, V. J., J. E. Ambler, and L. M. Fisher. 2000. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob. Agents Chemother. 44:3112-3117.
20. Hiasa, H., and M. E. Shea. 2000. DNA gyrase-mediated wrapping of the DNA strand is required for the replication fork arrest by the DNA gyrasequinolone-DNA ternary complex. J. Biol. Chem. 275:34780-34786.
21. Hooper, D. C. 1999. Mechanisms of quinolone resistance. Drug Resist. Updates 2:38-55.
22. Hooper, D. C. 2000. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 31:S24-S28.
23. Hooper, D. C. 2001. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis. 32:S9-S15.
24. Ince, D., and D. C. Hooper. 2000. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob. Agents Chemother. 44:3344-3350.
25. Ince, D., and D. C. Hooper. 2001. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2755-2764.
26. Ito, H., H. Yoshida, M. Bogaki-Shonai, T. Niga, H. Hattori, and S. Nakamura. 1994. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob. Agents Chemother. 38:2014-2023.
27. Janoir, C., E. Varon, M. D. Kitzis, and L. Gutmann. 2001. New mutation in ParE in a pneumococcal in vitro mutant resistant to fluoroquinolones. Antimicrob. Agents Chemother. 45:952-955.
28. Jones, R. N., M. A. Pfaller, and M. Stilwell. 2001. Activity and spectrum of BMS 284756, a new des-F(6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci. Diagn. Microbiol. Infect. Dis. 39:133-135.
29. Kaatz, G. W., and S. M. Seo. 1995. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 39:2650-2655.
30. Khodursky, A. B., and N. R. Cozzarelli. 1998. The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J. Biol. Chem. 273:27668-27677.
31. Lawrence, L. E., P. Wu, L. Fan, K. E. Gouveia, A. Card, M. Casperson, K. Denbleyker, and J. F. Barrett. 2001. The inhibition and selectivity, of bacterial topoisomerases by BMS-284756 and its analogues. J. Antimicrob. Chemother. 48:195-201.
32. Lu, T., X. L. Zhao, and K. Drlica. 1999. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob. Agents Chemother. 43:2969-2974.
33. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1994. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob. Agents Chemother. 38:1345-1355.
34. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship of the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888.
35. Novick, R. P. 1991. Genetic systems in staphylococci. Methods Enzymol. 204:587-636.
36. Pan, X. S., and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41:471-474.
37. Pan, X. S., and L. M. Fisher. 1998. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2810-2816.
38. Pan, X. S. and L. M. Fisher. 1999. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob. Agents Chemother. 43:1129-1136.
39. Roychoudbury, S., C. E. Catrenich, E. J. McIntosh, H. D. McKeever, K. M. Makin, P. M. Koenigs, and B. Ledoussal. 2001. Quinolone resistance in staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates. Antimicrob. Agents Chemother. 45:1115-1120.
40. Roychoudbury, S., T. L. Twinem, K. M. Makin, M. A. Nienaber, C. Y. Li, T. W. Morris, B. Ledoussal, and C. E. Catrenich. 2001. Staphylococcus aureus mutants isolated via exposure to nonfluorinated quinolones: detection of known and unique mutations. Antimicrob. Agents Chemother. 45:3422-3426.
41. Sanders, C. C. 2001. Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones. Clin. Infect. Dis. 32:S1-S8.
42. San, S., J. W. Sun, and C. Y. Lee. 1997. Molecular characterization and transcriptional analysis of type 8 capsule genes in Staphylococcus aureus. J. Bacteriol. 179:1614-1621.
43. Stahl, M. L., and P. A. Pattee. 1983. Confirmation of protoplast fusion-derived linkages in Staphylococcus aureus by transformation with protoplast DNA. J. Bacteriol. 154:406-412.
44. Takahata, M., J. Mitsuyama, Y. Yamashiro, M. Yonezawa, H. Araki, Y. Todo, S. Minami, Y. Watanabe, and H. Narita. 1999. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob. Agents Chemother. 43:1077-1084.
45. Takei, M., H. Fukuda, R. Kishii, and M. Ho̊saka. 2001. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45:3544-3547.
46. Trucksis, M., J. S. Wolfson, and D. C. Hooper. 1991. A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. J. Bacteriol. 173:5854-5860.
47. Varon, E., C. Janoir, M. D. Kitzis, and L. Gutmann. 1999. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:302-306.
48. Wang, J. C. 1998. Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine. Q. Rev. Biophys. 31:107-144.
49. Wigley, D. B., G. J. Davies, E. J. Dodson, A. Maxwell, and G. Dodson. 1991. Crystal structure of an N-terminal fragment of the DNA gyrase B protein. Nature 351:624-629.
50. Wu, P., L. E. Lawrence, K. L. Denbleyker, and J. F. Barrett. 2001. Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays. Antimicrob. Agents Chemother. 45:3660-3662.
51. Yague, G., J. E. Morris, X. S. Pan, K. A. Gould, and L. M. Fisher. 2002. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob. Agents Chemother. 46:413-419.
52. Yamagishi, J. I., T. Kojima, Y. Oyamada, K. Fujimoto, H. Hattori, S. Nakamura, and M. Inoue. 1996. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1157-1163.
53. Yoshida, H., M. Bogaki, M. Nakamura, L. M. Yamanaka, and S. Nakamura. 1991. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob. Agents Chemother. 35:1647-1650.
54. Yu, J.-L., L. L. Grinius, and D. C. Hooper. 2002. NorA functions as a multidrug transporter in everted membrane vesicles and proteoliposomes. J. Bacteriol. 184:1370-1377.
55. Zhao, B. Y., R. Pine, J. Domagala, and K. Drlica. 1999. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob. Agents Chemother. 43:661-666.
56. Zhao, X. L., J. Y. Wang, C. Xu, Y. Z. Dong, J. F. Zhou, J. Domagala, and K. Drlica. 1998. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob. Agents Chemother. 42:956-958.